XML 46 R33.htm IDEA: XBRL DOCUMENT v3.20.2

REVENUES (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Net Sales from Contracts with Customers by Global Business Unit

The following tables disaggregate our net sales by Global Business Unit (GBU) between the U.S. and international:

			Three months ended June 30,
												As Restated
			2020															2019
(in millions)			U.S.			International			Total			U.S.			International			Total
Renal Care 1			$	209		$	710		$	919		$	196		$	711		$	907
Medication Delivery 2			401			211			612			441			248			689
Pharmaceuticals 3			212			273			485			235			303			538
Clinical Nutrition 4			78			141			219			79			136			215
Advanced Surgery 5			94			74			168			143			88			231
Acute Therapies 6			72			114			186			44			88			132
Other 7			61			68			129			55			67			122
Total Baxter			$	1,127		$	1,591		$	2,718		$	1,193		$	1,641		$	2,834

			Six months ended June 30,
												As Restated
			2020															2019
(in millions)			U.S.			International			Total			U.S.			International			Total
Renal Care 1			$	413		$	1,376		$	1,789		$	388		$	1,373		$	1,761
Medication Delivery 2			862			440			1,302			847			476			1,323
Pharmaceuticals 3			443			569			1,012			467			581			1,048
Clinical Nutrition 4			160			279			439			156			264			420
Advanced Surgery 5			231			161			392			263			167			430
Acute Therapies 6			132			210			342			92			169			261
Other 7			103			141			244			100			129			229
Total Baxter			$	2,344		$	3,176		$	5,520		$	2,313		$	3,159		$	5,472

1Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.

2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.

3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.

4Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.

5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.

6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).

7Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.

Sales-type Lease, Lease Income

The components of lease revenue for the three and six months ended June 30, 2020 were:

(in millions)			Three months ended June 30, 2020			Six months ended June 30, 2020
Sales-type lease revenue			$	10		$	16
Operating lease revenue			14			28
Variable lease revenue			20			38
Total lease revenue			$	44		$	82

The components of lease revenue for the three and six months ended June 30, 2019 were:

(in millions)			Three months ended June 30, 2019			Six months ended June 30, 2019
Sales-type lease revenue			$	5		$	11
Operating lease revenue			15			30
Variable lease revenue			21			42
Total lease revenue			$	41		$	83

Operating Lease, Lease Income

The components of lease revenue for the three and six months ended June 30, 2020 were:

(in millions)			Three months ended June 30, 2020			Six months ended June 30, 2020
Sales-type lease revenue			$	10		$	16
Operating lease revenue			14			28
Variable lease revenue			20			38
Total lease revenue			$	44		$	82

The components of lease revenue for the three and six months ended June 30, 2019 were:

(in millions)			Three months ended June 30, 2019			Six months ended June 30, 2019
Sales-type lease revenue			$	5		$	11
Operating lease revenue			15			30
Variable lease revenue			21			42
Total lease revenue			$	41		$	83

X

- Definition

Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=119202524&loc=SL77919396-209981

+ Details

Name:	us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=119202524&loc=SL77919391-209981

+ Details

Name:	us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration